TECregen has completed a seed financing round worth CHF 10 million. The amount equals roughly EUR 10.7 million or USD 12.6 million. The investment will accelerate its research into thymus regeneration. The goal is to restore immune function in people with weakened immune systems.
The Boehringer Ingelheim Venture Fund led the round. LifeSpan Vision Ventures joined. Carma Fund and EOS BioInnovation also took part. High-Tech Grnderfonds made an investment. The JFG Life Sciences Foundation of the University of Basel and Zurich Cantonal Bank also contributed.
The funding will support TECregens development of biologics built to rejuvenate thymic epithelial cells. These cells guide the formation of T cells. T cells are central to immune strength. The company said the new capital will help push its technology towards clinical readiness. TECregen emphasised the value of targeting the thymus to rebuild immune resilience in people facing immune decline.
